Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, is sharing a shareholder letter from Renovaro CEO Mark R. Dybul, MD. In the letter, Dybul provides information about the definitive agreement the company recently signed with artificial intelligence company GEDiCube. In the letter, Dybul noted that the two companies decided to combine in order to accelerate a shared mission to transform medicine and promote healthy longevity through the synergistic applications of advanced AI technology and pioneering biotherapeutics. Dybul noted that he anticipates serving as CEO of the combined company.
The letter notes that the combined company will bring together two innovative platforms in AI and biotherapeutics that will offer comprehensive solutions spanning early cancer detection, diagnostic insights and targeted immunotherapies. Renovaro’s expertise is an advanced immunotherapy platform focused initially on deadly solid tumor cancers that have seen only slightly improved survival rates while GEDiCube brings an award-winning AI technology that has already exhibited potential to detect lung cancer early with 95% accuracy by analyzing complex molecular data. “By joining forces, our two technology divisions will collaborate to push new boundaries in precision diagnostics and targeted treatments,” said Renovaro BioSciences CEO Mark R. Dybul, MD, in the press release. “At the same time, we will maintain nimble independent operations, allowing each platform to advance rapidly. I am excited to lead this combined company alongside our esteemed leadership team and board members, who offer unparalleled experience across AI, healthcare, and biotechnology. We share an ambitious vision to leverage AI to improve patient outcomes by detecting diseases sooner and matching treatments more precisely to the individual. We believe that the coming months will be exciting as we prepare to realize this combination’s potential and deliver on our commitment to shareholders.”
To view the full shareholder letter, visit https://ibn.fm/MRmQI
About Renovaro BioSciences Inc.
Renovaro BioSciences has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases. For more information about the company, visit www.RenovaroBio.com.
NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB
About AINewsWire
AINewsWire (“AINW”) is a specialized communications platform with a focus on the latest advancements in artificial intelligence (“AI”), including the technologies, trends and trailblazers driving innovation forward. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, AINW brings its clients unparalleled recognition and brand awareness.
AINW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from AINewsWire, text “AI” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit www.AINewsWire.com
Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: https://www.AINewsWire.com/Disclaimer
AINewsWire
Los Angeles, CA
www.AINewsWire.com
310.299.1717 Office
Editor@AINewsWire.com
AINewsWire is powered by IBN
Adageis, a growing healthcare technology company, offers a unique streamlined and AI-powered software solution designed…
Beeline Holdings (NASDAQ: BLNE) has announced a disruptive new product that enables equity-rich homeowners to…
Adageis, a forward-thinking healthcare technology company, has a comprehensive suite of AI-powered solutions aimed at…
NVIDIA (NASDAQ: NVDA) is experiencing a stock surge, rising 5.3% on Thursday, even after issuing…
ONAR (OTCQB: ONAR) is a leading marketing technology company and marketing agency network focused on delivering…
Bionoid Pharma (OTC PINK: BINP) has rebranded as AI Maverick Intel, Inc., signaling a strategic…